Developmental Cell, Volume 36

Supplemental Information

Phosphorylation-Dependent Activation

of the ESCRT Function of ALIX

in Cytokinetic Abscission and Retroviral Budding

Sheng Sun, Le Sun, Xi Zhou, Chuanfen Wu, Ruoning Wang, Sue-Hwa Lin, and Jian Kuang



Figure S1. Supplemental data related to Figure 1. (A) IE and ME were prepared with EB freshly supplemented with 1 μ M microcystin and 1 mM ATP, and immunoprecipitated with indicated anti-ALIX antibodies. Input proteins and immunocomplexes were immunoblotted with indicated antibodies. (B) ME was first incubated with the TNT product of myc or myc-TSG101 at 4°C for 2 h, and then treated with CIP. IE, ME and the two samples of differently treated ME were immunoprecipitated with indicated antibodies, followed by immunoblotting with indicated antibodies. (C) PNSs from asynchronously growing HEK293 cells (Interphase cells) or mitotically arrested HEK293 cells (Mitotic cells) were fractionated by membrane flotation centrifugation. Same volumes of aliquots were taken and immunoblotted with indicated antibodies; membrane (M) and soluble (S) protein fractions are indicated. The average percentages of ALIX in the M fraction and SDs were determined from three independent experiments and plotted.



Figure S2. Supplemental data related to Figure 3. (A) Left: The phosphospecific sequence recognized by the #4381 antibody, and its alignment with the S718 surrounding sequence in ALIX. Right: SDS-denatured IE and ME (dIE and dME) were immunoblotted with the #4381 antibody after Ponc staining, and the arrow indicates the position of ALIX. (B) Left: Sequence of the phosphorylated ALIX peptide used for production of the anti-pS2 antibody. Right: The dIE and dME were immunoblotted with the anti-pS2 antibody after Ponc staining, and the arrow indicates the position of ALIX. (C) GST-ALIX_{nPRD} was mock-treated or phosphorylated with MEE or MEE plus CIP, and then immobilized onto GSH beads. Bound proteins were immunoblotted with the anti-pS2 antibody. (D) Immature oocytes and progesterone-matured oocyte extracts (MOE) were immunoblotted with MPM2. (E) GST-ALIX_{nPRD} was phosphorylated with freshly prepared IOE, MOE, or MOE plus CIP, and then immobilized onto GSH beads. Bound proteins were immunoblotted with the anti-pS2 entibody. (F) WT and S2A GST-ALIX_{nPRD} were mock treated or phosphorylated with MOE, and then immobilized onto GSH beads. Bound proteins were immunoblotted with the anti-pS2 antibody. Right for MOE, and then immobilized onto GSH beads. Bound proteins were immunoblotted with the anti-pS2 antibody. (F) WT and S2A GST-ALIX_{nPRD} were mock treated or phosphorylated with MOE, and then immobilized onto GSH beads. Bound proteins were immunoblotted with the anti-pS2 antibody.



Figure S3. Supplemental data related to Figure 5. (A&B) HeLa cells were transfected with indicated agents and cultured as done for Fig. 5A. Cell lysates were immunoblotted with indicated antibodies to visualize ALIX, mCherry-CHMP4b (A), mCherry-TSG101 (B) and actin. Fixed cells were immunostained with anti-tubulin antibody (green), and counterstained with DAPI (blue). The average percentages of mCherry positive cells with midbody localization of mCherry-CHMP4b and SDs (A) or mCherry-TSG101 (B) were determined from three independent experiments and plotted. Representative images are shown; the squares show the midbody areas to be enlarged. Solid and hollow arrowheads indicate the presence and absence of mCherry-CHMP4b (A) or mCherry-TSG101 (B) at the midbody, respectively. Scale bar: 50 µm. (C) HeLa cells were transfected with indicated siRNAs for 72 h, and cell lysates were immunoblotted with indicated antibodies to visualize ALIX and actin. Fixed cells were immunostained with an anti-tubulin antibody (red), and counterstained with DAPI (blue). The average percentages of midbody-stage cells or multinucleated cells and SDs were determined from three independent experiments and plotted. Representative images are shown; solid and hollow arrows indicate mononucleated and multinucleated cells, respectively, and hollow arrowheads indicate midbodies between daughter cells. Scale bar: 50 µm. (D) HeLa cells were transfected with indicated siRNAs for 72 h, and fixed cells were immunostained with an anti-tubulin antibody (green), and counterstained with DAPI (blue). Representative images are shown in which solid and hollow arrowheads indicate midbodies with normal and abnormal morphology, respectively. The squares on the right corner show the 3x enlarged midbody area. The percentages of abnormal midbodies were determined from at least 50 midbody-stage cells. Scale bar: 15 µm.

Prepare IE from HEK293 cells ectopically expressing GFP-ALIX Incubate IE with MEE plus GST or GST-p9 Dephosphorylate the mixture with IOE followed by IP with 1A3 or 3A9 antibody



Figure S4. Supplemental data related to Figure 6. IE from HEK293 cells ectopically expressing GFP-ALIX was processed as diagrammed (left panel). Input proteins (middle panel) and immunocomplexes (right panel) were immunoblotted with indicated antibodies to visualize GFP-ALIX, GST, GST-p9 and IgG-H.



Figure S5. Supplemental data related to Figure 7. (A) HEK293 cells ectopically expressing indicated forms of GFP-ALIX were processed as described for Fig. 7A. Same volumes of aliquots were taken and immunoblotted with indicated antibodies. (B) HEK293 cells transfected with indicated siRNAs and the plasmid for ΔPxY GFP-ALIX* were processed as described for Fig. 7 C&D. (C) HEK293 cells transfected with indicated siRNAs and the plasmid for ΔPxY GFP-ALIX* were processed as described as Fig. 7 E&F.

 Table S1. Sequences of siRNAs used in this study - related to Experimental Procedures

| Target | Name | Sequence | Source |
|------------------------|---------|-------------------------------|---------------|
| ALIX | si-ALIX | 5'-GAGAAGAAAUUGCAAGGUUdTdT-3' | Sigma-Genosys |
| Firefly GL3 luciferase | si-NC | 5'-CUUACGCUGAGUACUUCGAdTdT-3' | Sigma-Genosys |

| Vector | Source | Reference |
|---|---|-------------------|
| 1. pEGFP-C3-based mammalian expression | A gift from Dr. Masatoshi Maki (Nagoya, | (Shibata et al., |
| vector for GFP-ALIX | Japan) | 2004) |
| 1a. pEGFP-C3-based mammalian expression | Site-directed mutagenesis | new |
| vector for ALIX-siRNA-insensitive GFP-ALIX | of vector 1 | |
| (GFP-ALIX*) | | |
| 1b. pEGFP-C3-based mammalian expression | Site-directed mutagenesis | new |
| vector for S718A GFP-ALIX | of vector 1 | |
| 1c. pEGFP-C3-based mammalian expression | Site-directed mutagenesis | new |
| vector for S721A GFP-ALIX | of vector 1 | |
| 1d. pEGFP-C3-based mammalian expression | Site-directed mutagenesis | new |
| vector for S718A-S721A GFP-ALIX | of vector 1 | |
| 1e. pEGFP-C3-based mammalian expression | Site-directed mutagenesis | new |
| vector for S712A-S729A GFP-ALIX | of vector 1 | |
| 1f. pEGFP-C3-based mammalian expression | Site-directed mutagenesis | new |
| vector for S718A-S721A ALIX-siRNA- | of vector 1a | |
| insensitive GFP-ALIX (S2A GFP-ALIX*) | | |
| 1g. pEGFP-C3-based mammalian expression | Site-directed mutagenesis | new |
| vector for S712A-S729A ALIX-siRNA- | of vector le | |
| insensitive GFP-ALIX (S2A- GFP-ALIX*) | | |
| Th. pEGFP-C3-based mammalian expression | Site-directed mutagenesis | new |
| vector for S/18D-S/21D GFP-ALIX | of vector 1 | |
| 2. pCMV-based mammalian expression vector for | A gift from Dr. Masatoshi Maki (Nagoya, | (Katoh et al., |
| FLAG-CHMP4b | Japan) | 2003) |
| 3. pIRES2 based mammalian expression vector | A gift from Dr. Wesley I. Sundquist | (von Schwedler et |
| 10f FLAG-1SG101 | (Salt Lake City, U1) | al., 2003) |
| 4. pmCherry-C1-based expression | EaoPL and YhoL and insert it into the | new |
| vector for menerg-CHWP40 | ECOKI and Anoi and insert it into the | |
| | digestion with EcoRI and Sall | |
| 5 nmCherry-C1-based expression | PCR amplification of coding region of | new |
| vector for mCherry-TSG101 | TSG101 from pIRES2- | iie w |
| vector for menerry-156101 | FLAG_TSG101 followed by subcloning into | |
| | nmCherry-C1 vector (clontech) | |
| 6 pEV53B-based mammalian expression vector | A gift from Dr. John Olsen | (Olsen 1998) |
| for infection defective EIAV | (Chapel Hill, NC) | (0.000, 0, 0, 0) |
| 7. pCS2-MT based TNT expression vector for | PCR amplification of coding region of amino | new |
| myc-ALIX _{nPRD} | acid 706-786 of WT GFP-ALIX, followed by | |
| | subcloning into pCS2-MT vector (clontech) | |
| 8. pCS2-MT based TNT expression vector for | PCR amplification of coding region of amino | new |
| S718A-S721A myc-ALIX _{nPRD} | acid 706-786 of S718A-S721A GFP-ALIX, | |
| | followed by subcloning into pCS2-MT vector | |
| | (clontech) | |
| 9. pCS2-MT based TNT expression vector for | PCR amplification of coding region of amino | new |
| S712A-S729A myc-ALIX _{nPRD} | acid 706-786 of S712A-S729A GFP-ALIX, | |
| | followed by subcloning into pCS2-MT vector | |
| | (clontech) | |
| 10. pCS2-MT based TNT expression vector for | PCR amplification of coding region of amino | new |
| S718D-S721D myc-ALIX _{nPRD} | acid 706-786 of S718D-S721D GFP-ALIX, | |
| | tollowed by subcloning into pCS2-MT vector | |
| | (clontech) | |
| 11. pCS2-MT based TNT expression vector for | PCR amplification of coding region of | new |
| myc-18G101 | ISGIUI from pIKES2- | |
| | rLAU-150101, 10110Wed by subcioning into | |
| | DUSZ-IVEL VECTOR (CIONIECD) | 1 |

Table S2. Mammalian and bacterial expression vectors used in this study – related to Experimental Procedures

| 12 pCS2-HA based expression vector for HA- | PCR amplification of coding region of Plx1 | new |
|--|---|--------------------|
| Plx1 (Xenopus) | from pBluescript-Plx1(A gift from Dr. | |
| | William G. Dunphy (Kumagai and Dunphy, | |
| | 1996), followed by subcloning into pCS2-HA | |
| | vector (clontech) | |
| 13. pCS2-HA based expression vector for HA- | PCR amplification of coding region of K82R | new |
| K82R Plx1 (Xenopus) | Plx1 from pBluescript-K82R Plx1, followed | |
| | by subcloning into pCS2-HA vector | |
| | (clontech) | |
| 14. pGEX-4T3 based bacterial expression vector | PCR amplification of coding region of amino | new |
| GST-ALIX _{nPRD} | acid 706-786 of WT GFP-ALIX, followed by | |
| | subcloning into pGEX-4T3 vector (Amersham | |
| | Biosciences) | |
| 15. pGEX-4T3 based bacterial expression vector | Generated in our previous studies | (Pan et al., 2006) |
| for GST-ALIX _{Bro1} | | |
| 16. pGEX-4T3 based bacterial expression vector | Generated in our previous studies | (Zhou et al., |
| for GST-ALIX ₁₋₇₄₆ | | 2010) |
| 17. pGEX-4T3 based bacterial expression vector | PCR amplification of coding region of | new |
| for GST-CHMP4b | CHMP4b from FLAG-CHMP4b, followed by | |
| | subcloning into pGEX-4T3 vector (Amersham | |
| | Biosciences) | |
| 18. pGEX-4T3 based bacterial expression vector | A gift from Dr. Wesley I. Sundquist (Salt | (Fisher et al., |
| for GST-p9 ^{Gag} | Lake City, UT) | 2007) |

| Product | Primers (Forward/Reverse) | Template |
|--------------------------|--|----------------------------|
| 1a. ALIX-siRNA- | 5'-GAAGAAATTTGGGGAGGAGAATCGCGAGATTACAGCATGCAGCAG-3' | 1. WT |
| insensitive GFP- | 5'-CTGCTGCATGCTGTAATCTCGCGATCTCCTCCCCAAATTTCTTC-3' | GFP-ALIX |
| ALIX | | |
| 1b. S718A GFP- | 5'-CATTGCCAGAGAACCTGCTGCTGCTCCTTCAATTCCTACAC-3' | 1. WT GFP- |
| ALIX | 5 - GIGIAGGAAIIGAAGGAGGAGGAGGAGGIICICIGGGAAIG-5 | ALIX |
| | 5' GCAGGTGTAGGAATTGCAGGAGCACTAGGTTC 3' | I. WI GFP- |
| 1d \$7184-\$7214 | 5'-CATTGCCAGAGAACCTGCTGCTGCCACTCCTACACCTG.3' | 1 WT GFP- |
| GFP-ALIX | 5'-CAGGTGTAGGAATTGCAGGAGCAGCAGGTTCTCTGGCAATG-3' | ALIX |
| | | |
| 1e. S712A-S729A | WT to S712A: | 1. WT GFP- |
| GFP-ALIX | 5'-CTTAAAGGACTTGCAACAAGCCATTGCCAGAGAACCTAGTG-3' | ALIX |
| | 5'-CACTAGGTTCTCTGGCAATGGCTTGTTGCAAGTCCTTTAAG -3' | |
| | 5' CTACACCTGCGTATCAGGCCTCACCAGCAGGAGGAC 3' | |
| | 5'-GTCCTCCTGCTGGTGAGGCCTGATACGCAGGTGTAG-3' | |
| 1f. S718A-S721A | 5'-CATTGCCAGAGAACCTGCTGCTGCTGCAATTCCTACACCTG-3' | 1a. ALIX- |
| ALIX-siRNA- | 5'-CAGGTGTAGGAATTGCAGGAGCAGCAGGTTCTCTGGCAATG-3' | siRNA- |
| insensitive GFP- | | insensitive GFP- |
| ALIX | | ALIX |
| 1g. S712A-S729A | 5'-GAAGAAATTTGGGGAGGAGAGATCGCGAGATTACAGCATGCAGCAG-3' | 1e. S712A- |
| ALIX-siRNA- | 5'-CTGCTGCATGCTGTAATCTCGCGATCTCCTCCCCAAATTTCTTC-3' | S729A GFP- |
| insensitive GFP- | | ALIX |
| ALIA 16 \$7180 \$7210 | | 1 WT GED |
| GFP-ALIX | 5'-CGCAGGTGTAGGAATATCAGGAGCATCAGGTTCTCTGGCAATGC-3' | ALIX |
| 5 mChammy | 5' TAACTECACCT ATCCCCCTCTCCCACAC 2' (Vho I) | 2 mIDES2 |
| 5. mCherry- | 5° TAAGAATTCTCAGTAGAGGTCACTGAGACCG 3° (Zilo I) | 5. pikes2- FLAG TSG101 |
| 150101 | | 1 U/T CEP |
| 7. pCS2-MT- | 5'-TAAGAATTCATTAAAGGACTTGCAACAAAGCATTG-3' (EcoRI) | I. WT GFP- |
| ALIA _{nPRD} | 5 - TAACTCGAGTGGCGCAGCAGTCCC-5 (Xfl01) | ALIX |
| 8. pCS2-MT- | 5'-TAAGAATTCATTAAAGGACTTGCAACAAAGCATTG-3' (EcoRI) | 1d. S718A- |
| S/18A-S/21A | 5'-TAACTCGAGTGGCGCAGCAGTCCC-3' (Xho I) | S721A GFP- |
| $ALIA_{nPRD}$ | | ALIA 1. \$7124 \$720 |
| 9. pC32-W11- | 5^{-1} | $\Delta GFP_{\Delta I} IX$ |
| ALIX, PRD | | A OIT-ALIA |
| 10. pCS2-MT- | 5'-TAAGAATTCATTAAAGGACTTGCAACAAAGCATTG-3' (EcoRI) | 1h. S718D- |
| \$718D-\$721D | 5'-TAACTCGAGTGGCGCAGCAGTCCC-3' (Xho I) | S721D GFP- |
| myc-ALIX _{nPRD} | | ALIX |
| 11. pCS2-MT- | 5'- TAAGAATTCAATGGCGGTGTCGGAGAG-3' (EcoRI) | 3. pIRES2- |
| TSG101 | 5'- TAACTCGAGTCAGTAGAGGTCACTGAGACCG-3' (Xho I) | FLAG-TSG101 |
| 12. pCS2-HA- | 5'-AATGGGCCCTCAAGTGGCCGGTAAGAAAC-3' (Apa I) | pBluescript-Plx1 |
| Plx1 (Xenopus) | 5'-GCCTCTAGAGCCGAGGCCTTTACGTGTGC-3' (Xba I) | |
| 13. pCS2-HA- | 5'-AATGGGCCCTCAAGTGGCCGGTAAGAAAC-3' (Apa I) | pBluescript-Plx1 |
| Plx1 K82R | 5'-GCCTCTAGAGCCGAGGCCTTTACGTGTGC-3' (Xba I) | K82R |
| (Xenopus) | | |
| 14. pGEX-4T3- | 5'-TAAGAATTCCTTAAAGGACTTGCAACAAAGCATTG-3' (EcoRI) | 1. WT GFP- |
| ALIX _{nPRD} | 5'-TAACTCGAGTGGCGCAGCAGTCCC-3' (Xho I) | ALIX |
| 17. pGEX-4T3- | 5'- TAAGAATTCCATGTCGGTGTTCGGGAAG-3' (EcoRI) | 2. FLAG- |
| CHMP4b | 5'- TAACTCGAGTTACATGGATCCAGCCCAG-3' (Xho I) | CHMP4b |

Table S3. PCR primers used for site-directed mutagenesis and making vectors – related to Experimental Procedures

| Antibody | Recognition | Туре | Source | Use |
|----------------|---------------------|------------|------------------------|---------------------|
| 1A3 anti-ALIX | ALIX (Y319)/ | Mouse | Made in our previous | Immunoblotting |
| | Xp95(Y318) | monoclonal | studies | Immunoprecipitation |
| 1A12 anti- | ALIX (05 700 | Mouse | Made in our previous | Immunoprecipitation |
| ALIX | 1 12011 1003-709 | monoclonal | studies | |
| 2H12 anti- | ALIX FOR market | Mouse | Made in our previous | Immunoprecipitation |
| ALIX | r 1217 1F6/6 pocket | monoclonal | studies | minunoprecipitation |
| 3A9 anti-ALIX | ALIX (05.700 | Mouse | Made in our previous | Immunoblotting |
| | 112111005-709 | monoclonal | studies | Immunoprecipitation |
| anti-actin | Actin | Mouse | Sigma-Aldrich | Immunoblotting |
| | | monoclonal | Cat#: A5441 | 6 |
| anti-tubulin | Alpha-tubulin | Rabbit | Cell Signaling | Immunostaining |
| | I | monoclonal | Cat#: 2125S | 6 |
| anti-CA | EIAV capsid | Mouse | A gift from Dr. Robert | Immunoblotting |
| | antigen (CA) | monoclonal | Mealey (Pullman, WA) | 6 |
| anti-CHMP4b | CHMP4b | Rabbit | Santa Cruz | Immunoblotting |
| | | polyclonal | Cat#: sc-134946 | |
| anti-EEA1 | EEA1 | Rabbit | Epitomics | Immunoblotting |
| | | monoclonal | Cat#: 3704-1 | 6 |
| anti-EGFR | EGFR | Rabbit | Epitomics | Immunoblotting |
| | | monoclonal | Cat#: 1902-1 | 6 |
| anti-ERK1 | ERK1 | Rabbit | Santa Cruz | Immunoblotting |
| | | polyclonal | Cat#:sc-94 | 6 |
| anti-ERK2 | ERK2 | Rabbit | Santa Cruz | Immunoblotting |
| | | polyclonal | Cat#:sc-154 | - C |
| anti-FLAG | FLAG epitope | Mouse | Pierce | Immunoblotting |
| | 1 1 | monoclonal | Cat#: MA1-918781 | C C |
| anti-FLAG | FLAG epitope | Rabbit | Santa Cruz | Immunoblotting |
| | | polyclonal | Cat#: sc-807 | Immunoprecipitation |
| anti-GFP | GFP | Mouse | Santa Cruz | Immunoblotting |
| | | monoclonal | Cat#: sc-9996 | Immunoprecipitation |
| | | | | Immunostaining |
| anti-GST | GST | Rabbit | Santa Cruz | Immunoblotting |
| | | polyclonal | Cat#: sc-459 | |
| anti-HA | HA epitope | Rabbit | Santa Cruz | Immunoblotting |
| | | polyclonal | Cat#: sc-805 | Immunoprecipitation |
| IgG | IgG | Mouse | Sigma-Aldrich | Immunoprecipitation |
| | | | Cat#: I5381-10MG | |
| IgG | IgG | Rabbit | Sigma-Aldrich | Immunoprecipitation |
| | | | Cat#: I5006-10MG | |
| anti-myc | myc epitope | Rabbit | Santa Cruz | Immunoblotting |
| | | polyclonal | Cat#: sc-789 | Immunoprecipitation |
| MPM2 | Mitotic | Mouse | Lab reserve | Immunoblotting |
| | phosphoproteins | monoclonal | | |
| #4381 antibody | PKD substrates | Rabbit | Cell Signaling | Immunoblotting |
| | | polyclonal | Cat#: 4381 | Immunoprecipitation |
| anti-pS2 | p-S718-S721-ALIX | Rabbit | Made in this study | Immunoblotting |
| antibody | | polyclonal | | Immunoprecipitation |
| anti-p-ERK | p-ERK1/2 at Tyr | Mouse | Santa Cruz | Immunoblotting |
| | 204 | monoclonal | Cat#: sc7383 | |
| antı-RFP | mCherry epitope | Mouse | Pierce | Immunoblotting |
| | | monoclonal | Cat#: MA5-15257 | T 11 |
| antı-p-Tyr | phosphotyrosine | Mouse | Cell Signaling | Immunoblotting |
| | T00101 | monoclonal | Cat#: 9416 | T |
| anti-18G101 | 18G101 | Rabbit | Epitomics | Immunoblotting |
| | | monocional | Cat#: 55//-1 | |

Table S4. Antibodies used in this study – related to Experimental Procedures

SUPPLEMENTAL EXPERIMENTAL PROCEDURES

In vitro phosphorylation of ALIX fragments with Xenopus extracts and GST pull-down

In vitro transcription and linked translation of proteins was performed by using TNT® Quick Coupled Transcription/Translation System (Promega) according to the manufacturers' instructions. GST and GST-tagged proteins were produced and purified using our standard procedures (Che et al., 1997). Phosphorylation reaction included one volume of substrate proteins and three volumes of IOE or MEE. The reaction was performed at 22°C for 2 h unless otherwise indicated, and terminated by adding SDS-PAGE sample buffer. The Plk1 inhibitor BI-2536 (Axon Medchem), the PKD inhibitor CID755673 (BioVision Inc.), and the pan-kinase inhibitor staurosporine (LC Laboratories) were all dissolved in Dimethyl sulfoxide (DMSO), and added to MEE at 4°C whenever indicated 15 min prior to the phosphorylation reaction to reach a final concentration of 2 μ M, 5 μ M and 5 μ M, respectively. GST tagged proteins were immobilized onto glutathione (GSH) beads (GenScript), and GST pull-down was performed at 4°C for 2 h. After GSH beads were washed five times with EB, proteins remaining on the beads were eluted with SDS-PAGE sample buffer for immunoblotting.

Immunostaining and fluorescence microscopy

Transfected HeLa cells were subcultured into chamber slides (Nunc Lab-Tek) coated with poly-D-Lysine (Cultrex) and cultured for 48 h before being fixed with 4% (w/v) of Paraformaldehyde at room temperature for 20 min. Fixed cells were permeabilized with 0.2% Triton X-100 in PBS followed by blocking with 1x blocking buffer (1% BSA, 0.25% horse serum, 0.2% Triton X-100 in PBS). Blocked cells were first stained with primary antibodies in 0.1x blocking buffer at 4°C overnight, and then with Alexa Fluor 568, Alexa Fluor 488 or Alexa Fluor 647 conjugated secondary antibodies in TBST (0.1% Triton X-100 in TBS) at room temperature for 1 h. Nuclei were stained with DAPI (Sigma). Images were acquired using MetaMorph software (7.7.5.0) on ZEISS Axioplan2 image system (Objective: plan-NEOFLUAR 20×/0.50). For obtaining the percentages of the midbody localization of mCherry-CHMP4b or mCherry-TSG101 in midbody-staged cells with knockdown of ALIX, at least 10 clearly mCherry positive cells were counted for each experiment. For obtaining the percentages of the midbody localization of mCherry-CHMP4b in midbody-staged cells ectopically expressing both GFP-ALIX* and mCherry-CHMP4b, at least 10 clearly double positive cells were counted for each experiment. For obtaining the percentages of multinucleated or midbody-staged cells induced by ALIX knockdown, at least 200 cells were counted for each experiment. For obtaining the percentages of multinucleated or midbody-staged cells ectopically expressing GFP or GFP-ALIX*, at least 100 clearly GFP-positive cells were counted for each experiment. There are four types of GFP-ALIX transfected cells under our fluorescence microscope. (i) No over-background green signal. (ii) Low over-background green signal without clear cell contour. (iii) Easily discernible over-background green signal with clear cell contour and specific localization in the cytoplasm. (iv) Very bright green cells with rounded cell shape, suggesting cell toxicity. We specifically examined the third type of cells.

Generation of rabbit polyclonal antibodies recognizing phosphorylated Ser718 and Ser721 at ALIX

To prepare antigen, a synthetic phosphopeptide consisting of the residues 711 to 724 of ALIX and phosphorylated at both Ser718 and Ser721 (CSIAREP(pS)AP(pS)IPT) was conjugated to keyhole limpet hemocyanin (KLH). To generate rabbit polyclonal antibodies, rabbits were immunized with the conjugated phosphopeptide for 42 days, and immunesera were collected. The IgG fraction of the antibodies was purified by protein G affinity chromatography. The phosphospecificity of the purified antibodies were evaluated with the enzyme-linked immune sorbent assay (ELISA).

SUPPLEMENTAL REFERENCES

Che, S., Weil, M.M., Nelman-Gonzalez, M., Ashorn, C.L., and Kuang, J. (1997). MPM-2 epitope sequence is not sufficient for recognition and phosphorylation by ME kinase-H. FEBS Letter *413*, 417-423.

Fisher, R.D., Chung, H.Y., Zhai, Q., Robinson, H., Sundquist, W.I., and Hill, C.P. (2007). Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell 128, 841-852.

Katoh, K., Shibata, H., Suzuki, H., Nara, A., Ishidoh, K., Kominami, E., Yoshimori, T., and Maki, M. (2003). The ALG-2interacting protein Alix associates with CHMP4b, a human homologue of yeast Snf7 that is involved in multivesicular body sorting. J Biol Chem *278*, 39104-39113. Epub 32003 Jul 39114.

Kumagai, A., and Dunphy, W.G. (1996). Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273, 1377-1380.

Olsen, J.C. (1998). Gene transfer vectors derived from equine infectious anemia virus. Gene Ther 5, 1481-1487.

Pan, S., Wang, R., Zhou, X., He, G., Koomen, J., Kobayashi, R., Sun, L., Corvera, J., Gallick, G.E., and Kuang, J. (2006). Involvement of the adaptor protein Alix in actin cytoskeleton assembly. J Biol Chem 285, 34640-34650.

Shibata, H., Yamada, K., Mizuno, T., Yorikawa, C., Takahashi, H., Satoh, H., Kitaura, Y., and Maki, M. (2004). The penta-EF-hand protein ALG-2 interacts with a region containing PxY repeats in Alix/AIP1, which is required for the subcellular punctate distribution of the amino-terminal truncation form of Alix/AIP1. J Biochem (Tokyo) *135*, 117-128.

von Schwedler, U.K., Stuchell, M., Muller, B., Ward, D.M., Chung, H.Y., Morita, E., Wang, H.E., Davis, T., He, G.P., Cimbora, D.M., et al. (2003). The protein network of HIV budding. Cell 114, 701-713.

Zhou, X., Si, J., Corvera, J., Gallick, G.E., and Kuang, J. (2010). Decoding the intrinsic mechanism that prohibits ALIX interaction with ESCRT and viral proteins. Biochem J 432, 525-534.